The Transverse Myelitis market is significantly influenced by autoimmune factors and their association with neurological disorders. Transverse myelitis is often linked to autoimmune conditions where the immune system mistakenly attacks the spinal cord, leading to inflammation. The increasing prevalence of autoimmune disorders contributes to the growth of the market.
Markets are affected by the fact that it is the contagious agents like the viruses that will take a center stage and are to be blamed for causing transverse myelitis. Some examples of a viral infections which lead to the development of shingles, herpes simplex, varicella-zoster, and other diseases. Global incidence of viral infections determines the prevalence of ta in the general population.
The affected population, ageing, are involved in shaping market size for transverse myelitis. Nonetheless, sadly it can come into many persons at any age, which consequently may lead to a variation in prevalence within different age groups. It is the demographics that help to focus in the health-care planning, and determine who gets what and where.
Continuous progress of research and development in the field of neurological diagnosis is one of the factors that determines the industry of neuro diagnostics. Due to progress of the radiological technology for detection of illness, i.e. magnetic resonance imaging (MRI), the accuracy of transverse myelitis diagnosis increased, the blood circulation in the process of diagnosis shortened which resulted in speedy diagnosis and timely treatment. Technology advances in diagnostics modifies the medical results and trends as well as commercial doings.
Immunomodulatory therapeutics’ development and subsequent adoption will be key contributors in rising trends of the market for transverse myelitis. The efficacy of these therapy modalities is achieved by the ability to regulate the immune system, which results in the decreasing of inflammation in spinal cord. The changing landscape in immunomodulatory treatment is showing impact on the way care is being provided to the patients and also introducing newness in the market of the evolving strategies.
Increased patient education and awareness initiatives impact the market. Awareness campaigns about transverse myelitis symptoms, risk factors, and available treatments promote early detection and intervention. Patient empowerment through education influences healthcare-seeking behavior and contributes to improved outcomes.
The market is shaped by the participation in clinical trials and research funding dedicated to transverse myelitis. Investigational treatments, emerging therapies, and collaborative research efforts contribute to advancements in understanding the condition. Research funding influences the development of novel interventions and shapes the future landscape of the market.
Report Attribute/Metric | Details |
---|---|
Growth Rate | 6.60% (2023-2030) |
Transverse Myelitis Market Size was valued at USD 0.20 Billion in 2023. The Global Transverse Myelitis industry is projected to grow from USD 0.30 Billion in 2024 to USD 0.40 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.23% during the forecast period (2024 - 2032).Transverse myelitis is a neurological disease caused by inflammation of both sides of one section of the spinal cord. This condition generally damages the insulating material covering the nerve cell fibers (myelin).
Transverse myelitis can occur at any age. According to the Columbia University Department of Neurology, this disease most often occurs in children ages 10 to 19 years and in adults aged 30 to 39 years. The inflammation leading to transverse myelitis can result as a side effect of a number of other conditions such as measles, viral infections, lyme disease, syphilis, viral infections, and bacterial infections among others. The common symptoms of the disease include back or neck pain, weakness in arms or legs, abnormal sensations in the legs, loss of bowel control and sensory symptoms such as numbness.
The factors such as growing prevalence of transverse myelitis, rising prevalence of diseases which can lead to transverse myelitis such as viral infections and some cancers, increasing in research and development activities, and rising expenditure on healthcare sector by the government in developed as well as developing economies is expected to fuel the transverse myelitis market. According to the National Multiple Sclerosis Society, it is estimated that about 1,400 new cases of transverse myelitis are diagnosed each year in the US. According to the same source, it is estimated that about 33,000 American population have some type of disability resulting from transverse myelitis.
Despite the drivers, high cost associated with the diagnosis and treatment of transverse myelitis can hamper the growth of the market over the assessment period.
The transverse myelitis market has been segmented into diagnosis, treatment, end user, and region.
The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), lumbar puncture, blood tests, and others.
The market, by treatment, has been segmented into intravenous steroids, plasma exchange therapy, antiviral medication, pain medications, physical therapy, occupational therapy, psychotherapy, and others. The pain medication has been further segmented into chronic pain medication and nerve pain medication. The chronic pain segment has been further segmented into acetaminophen, ibuprofen, and naproxen sodium. The nerve pain medication has been segmented into sertraline, gabapentin, and pregabalin.
On the basis of end user, the market has been segmented into hospitals & clinics, diagnostic centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transverse myelitis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European transverse myelitis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The transverse myelitis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transverse myelitis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the transverse myelitis market owing to a well-developed healthcare sector, rising prevalence of transverse myelitis, and a relatively large number of research and development activities. According to the Centers for Disease Control and Prevention (CDC), total national expenditure was USD for 3.3 trillion in 2016.
Europe is expected to hold the second largest position in the transverse myelitis market. The market growth in this region is attributed to the rising incidence of transverse myelitis and rising government expenditure for the healthcare sector. According to the Transverse Myelitis Society, transverse myelitis has an incidence of 300 new cases per year in the UK.
The transverse myelitis market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, growing awareness about rare diseases, and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector, increasing occurrence of transverse myelitis and growing government initiatives for the healthcare sector. According to an article published in the NCBI in May 2018, the adult prevalence rate for Emirati citizens was 2.46 per 100,000 citizens for monophasic transverse myelitis.
Key players
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)